amitriptyline has been researched along with Growth Disorders in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hill, RM | 1 |
| Verniaud, WM | 1 |
| Horning, MG | 1 |
| McCulley, LB | 1 |
| Morgan, NF | 1 |
1 other study available for amitriptyline and Growth Disorders
| Article | Year |
|---|---|
Infants exposed in utero to antiepileptic drugs. A prospective study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Amitriptyline; Amniotic Fluid; Anticonvulsants; Chro | 1974 |